var data={"title":"Sapropterin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Sapropterin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/341990?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=sapropterin-drug-information\" class=\"drug drug_general\">see &quot;Sapropterin: Drug information&quot;</a> and <a href=\"topic.htm?path=sapropterin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Sapropterin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23322581\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Kuvan</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27147560\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Kuvan</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13706445\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=sapropterin-drug-information\" class=\"drug drug_general\">see &quot;Sapropterin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Phenylalanine hydroxylase (PAH) deficiency disorders (eg, hyperphenylalaninemia, phenylketonuria [PKU]), adjunct treatment:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children &le;6 years: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial: 10 mg/kg/dose once daily; adjust dose after 1 month based on phenylalanine levels; if phenylalanine levels have not decreased from baseline after 1 month of therapy, increase dose to 20 mg/kg/dose once daily; if still no response after 1 month of therapy at the higher dose (20 mg/kg/day) then discontinue sapropterin (nonresponder) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Usual maintenance range: 5 to 20 mg/kg/dose once daily, dosage should be individualized based on patient response. <b>Note:</b> In clinical trials of patients &ge;7 months, doses were rounded to the nearest 100 mg increment so dosages up to 24 mg/kg/day were used (Burton 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;7 years and Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial: 10 to 20 mg/kg/dose once daily; adjust dose after 1 month based on phenylalanine levels: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial dose 10 mg/kg/dose: If phenylalanine levels have not decreased from baseline after 1 month of therapy, increase dose to 20 mg/kg/dose once daily; if still no response after 1 month of therapy at the higher dose (20 mg/kg/day) then discontinue sapropterin (nonresponder)  </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial dose 20 mg/kg/dose:  If no response after 1 month of therapy, discontinue sapropterin (nonresponder)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Usual maintenance range: 5 to 20 mg/kg/dose once daily; dosage should be individualized based on patient response. <b>Note:</b> In clinical trials of patients &ge;7 months, doses were rounded to the nearest 100 mg increment so dosages up to 24 mg/kg/day were used (Burton 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: Phenylalanine hydroxylase (PAH) deficiency disorders (eg, hyperphenylalaninemia, phenylketonuria [PKU]), adjunct treatment: Oral: Initial: 10 to 20 mg/kg once daily; adjust after 1 month based on blood phenylalanine levels (if phenylalanine levels do not decrease from baseline after initiating 10 mg/kg, increase dose to 20 mg/kg once daily); discontinue if phenylalanine levels do not decrease after 1 month of treatment at 20 mg/kg/day (nonresponder). Maintenance range: 5 to 20 mg/kg once daily </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5568667\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Packet, Oral, as dihydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kuvan: 100 mg (1 ea, 30 ea); 500 mg (1 ea, 30 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Soluble, Oral, as dihydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kuvan: 100 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24036978\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13706446\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer with food, preferably at the same time each day; a missed dose should be taken as soon as possible, but 2 doses should not be taken on the same day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Powder for oral solution: Dissolve powder for oral solution in water or apple juice or mix in a small amount of soft foods, such as apple sauce or pudding, prior administration. Take within 30 minutes of dissolution. <b>Note:</b> For use in infants and young children, sapropterin has shown similar stability when mixed with phenylalanine-free formula, applesauce, and pudding (Burton 2011a). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablets: Swallow tablets whole or dissolve tablets in water or apple juice. Dose should be consumed within 15 minutes of dissolution; may rinse remaining tablet residue (with more water or apple juice) and drink. Tablets may also be crushed and then mixed in a small amount of soft food, such as apple sauce or pudding.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5568649\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F) permitted. Protect from moisture.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13706416\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Reduction of  blood phenylalanine (PHE) levels in patients with hyperphenylalaninemia caused by tetrahydrobiopterin (BH4)-responsive phenylketonuria (PKU) in conjunction with a PHE-restricted diet (FDA approved in ages &ge;1 month and adults) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5568565\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Sapropterin may be confused with cyproterone</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5568582\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-4em;margin-left:4em;\">Central nervous system: Headache</p>\n    <p style=\"text-indent:-4em;margin-left:4em;\">Gastrointestinal: Diarrhea, vomiting</p>\n    <p style=\"text-indent:-4em;margin-left:4em;\">Respiratory: Cough, nasal congestion, pharyngolaryngeal pain, rhinitis (infants and children), rhinorrhea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylaxis, gastritis, gastrointestinal hemorrhage, hemorrhage (postprocedural), hyperactivity, myocardial infarction, peripheral edema, seizure (including seizure exacerbation), upper respiratory tract infection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5568576\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Hypersensitivity to sapropterin or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5568577\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastritis: Gastritis has been reported; monitor patients for gastritis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperactivity: Hyperactivity has been observed; monitor patients for hyperactivity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions, including anaphylaxis and rash, have occurred; not recommended for use in patients with a history of anaphylaxis to sapropterin. Discontinue use and initiate appropriate medical treatment in patients who experience anaphylaxis. Dietary phenylalanine (PHE) restrictions should be continued in patients who experience anaphylaxis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypophenylalaninemia: Some patients my experience low blood phenylalanine levels. Patients &lt;7 years treated at 20 mg/kg daily are at increased risk for hypophenylalaninemia as compared to patients &ge;7 years.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Has not been studied in patients with hepatic impairment. Monitor carefully; hepatic damage has been associated with impaired phenylalanine metabolism.  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Phenylketonuria: Phenylalanine (PHE) levels should be monitored and maintained within the target range during sapropterin treatment. Upon diagnosis, blood PHE levels should be lowered into the desired treatment range (120 to 360 micromol/L) as quickly as possible; infants with levels &gt;600 micromol/L require treatment, although treatment may be initiated at &ge;360 micromol/L; if testing is done in early infancy, it is recommended to initially lower blood PHE to 480 to 600 micromol/L  (Vockley, 2014). Prolonged high levels of phenylalanine can result in severe neurologic damage, including behavioral abnormalities, delayed speech, microcephaly, seizures, and severe mental retardation. Low levels of phenylalanine are associated with catabolism and protein breakdown. Dietary management of phenylalanine intake is required to ensure nutritional balance and adequate phenylalanine control. Monitor blood PHE levels during treatment (frequently in children). PHE blood level testing at doses &lt;20 mg/kg may underestimate response rate (Vockley, 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Has not been studied in patients with renal impairment; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric:  Children younger than 7 years treated with doses of 20 mg/kg/day are at increased risk for low levels of blood phenylalanine (hypophenylalaninemia). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nonresponders: Response to sapropterin treatment is established through treatment (cannot be predetermined by lab testing). Patients whose phenylalanine levels do not decrease after treatment at 20 mg/kg/day for 1 month are considered nonresponders.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300027\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5568645\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=17134&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Sapropterin may enhance the adverse/toxic effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: May decrease the serum concentration of Sapropterin. Specifically, methotrexate may decrease tissue concentrations of tetrahydrobiopterin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: Sapropterin may enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PRALAtrexate: May decrease the serum concentration of Sapropterin. Specifically, pralatrexate may decrease tissue concentrations of tetrahydrobiopterin.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5568572\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5568573\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. High levels of maternal phenylalanine are associated with congenital heart disease, developmental delay, facial dysmorphism, learning difficulties, and microcephaly. Phenylalanine (PHE) concentrations should be normalized prior to conception. Fetal development is optimal when PHE concentrations &lt;360 micromol/L are achieved prior to conception (Vockley 2014). Dietary control with proper supplementation is recommended during pregnancy. Maternal PHE requirements may change throughout pregnancy; frequent testing and dietary modifications may be necessary (Vockley 2014). Some clinicians recommend that dietary control be achieved for at least 4 weeks prior to conception; however, studies suggest that as long as control is achieved by 10 weeks of pregnancy, teratogenic effects of untreated maternal phenylketonuria can be decreased (Koch 2003; Maillot 2007). In addition to standard fetal monitoring, fetal echocardiography is recommended at 18 to 22 weeks gestation (Vockley 2014). Pregnant women exposed to sapropterin are encouraged to enroll in the Kuvan pregnancy registry (800-983-4537).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13706447\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood phenylalanine levels (baseline, after 1 week of treatment, periodically for first month, regularly thereafter); children may require more frequent monitoring; blood pressure in patients taking concomitant PDE-5 inhibitors (eg, sildenafil, vardenafil, tadalafil); patients with renal or hepatic impairment; change in neurologic status in patients taking concurrent levodopa; signs and symptoms of gastritis; hyperactivity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Guideline recommended monitoring for patients with phenylalanine hydroxylase deficiency (Vockley 2014):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Newly diagnosed infants: Monitor phenylalanine (PHE) and tyrosine (TYR) frequently until the PHE concentrations stabilize, then monitor PHE weekly until age 1 (increase frequency during rapid growth or dietary transitions)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents and Adults who are stable: Monitor PHE monthly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If formal nutritional assessment suggests suboptimal dietary intake or for over reliance on nutritionally incomplete medical foods: Consider monitoring plasma amino acids (full panel), transthyretin, albumin, CBC, ferritin, 25-OH vitamin D, vitamin B<sub>12</sub>, red blood cell essential fatty acids, trace minerals (copper, selenium, zinc), vitamin A, comprehensive metabolic panel, and folic acid.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28209766\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Phenylalanine hydroxylase deficiency, blood phenylalanine goal range: 120 to 360 micromol/L (Vockley 2014)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5568650\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Sapropterin is a synthetic form of the cofactor BH4 (tetrahydrobiopterin) for the enzyme phenylalanine hydroxylase (PAH). PAH hydroxylates phenylalanine to form tyrosine. BH4 activates residual PAH enzyme, improving normal phenylalanine metabolism and decreasing phenylalanine levels in sapropterin responders. Approximately 25% to 50% of patients with PAH deficiency are responsive to sapropterin (Vockley, 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5568652\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Within 24 hours; maximum effect: up to 1 month</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Absorption is enhanced when administered with food (high fat/high calorie); absorption via intact tablet administration is greater than dissolved tablet administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: The enzymes dihydrofolate reductase and dihydropteridine reductase are responsible for the metabolism and recycling of BH4.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~7 hours (range: 4-17 hours)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16321796\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (Kuvan Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $44.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $221.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet,Dispersible</b> (Kuvan Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (120): $5,313.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961933\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Kuvan (AR, AT, AU, BB, BE, BR, CH, CN, CR, CZ, DE, DK, DO, EE, ES, FR, GB, GT, HN, HR, IE, IL, IS, KR, LT, LU, LV, MT, NI, NL, NO, NZ, PA, PL, PT, RO, SE, SI, SK, SV, TW, UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Burton BK, Adams DJ, Grange DK, et al, &quot;Letters to the Editor: Reply: Tetrahydrobiopterin and Phenylketonuria,&quot; <i>J Pediatr</i>, 2011a, 158:864-5.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burton BK, Adams DJ, Grange DK, et al, &quot;Tetrahydrobiopterin Therapy for Phenylketonuria in Infants and Young Children,&quot; <i>J Pediatr</i>, 2011, 158(3):410-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sapropterin-pediatric-drug-information/abstract-text/20884009/pubmed\" target=\"_blank\" id=\"20884009\">20884009</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burton BK, Grange DK, Milanowski A, et al, &ldquo;The Response of Patients With Phenylketonuria and Elevated Serum Phenylalanine to Treatment With Oral Sapropterin Dihydrochloride (6R-Tetrahydrobiopterin): A Phase II, Multicentre, Open-Label, Screening Study,&rdquo; <i>J Inherit Metab Dis</i>, 2007, 30(5):700-7. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sapropterin-pediatric-drug-information/abstract-text/17846916/pubmed\" target=\"_blank\" id=\"17846916\">17846916</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koch R, Hanley W, Levy H, et al, &ldquo;The Maternal Phenylketonuria International Study: 1984-2002,&rdquo; <i>Pediatrics</i>, 2003, 112(6 Pt 2):1523-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sapropterin-pediatric-drug-information/abstract-text/14654658/pubmed\" target=\"_blank\" id=\"14654658\">14654658</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kuvan tablets (sapropterin) [prescribing information]. Novato, CA: BioMarin Pharmaceutical Inc; April 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levy H, Burton B, Cederbaum S, et al, &ldquo;Recommendations for Evaluation of Responsiveness to Tetrahydrobiopterin (BH4) in Phenylketonuria and Its Use in Treatment,&rdquo; <i>Mol Genet Metab</i>, 2007, 92(4):287-291. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sapropterin-pediatric-drug-information/abstract-text/18036498/pubmed\" target=\"_blank\" id=\"18036498\">18036498</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levy HL, Milanowski A, Chakrapani A, et al, &ldquo;Efficacy of Sapropterin Dihydrochloride (Tetrahydrobiopterin, 6R-BH4) for Reduction of Phenylalanine Concentration in Patients With Phenylketonuria: A Phase III Randomised Placebo-Controlled Study,&rdquo; <i>Lancet</i>, 2007, 370(9586):504-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sapropterin-pediatric-drug-information/abstract-text/17693179/pubmed\" target=\"_blank\" id=\"17693179\">17693179</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maillot F, Cook P, Lilburn M, et al, &ldquo;A Practical Approach to Maternal Phenylketonuria Management,&rdquo; <i>J Inherit Metab Dis</i>, 2007, 30(2):198-201.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vockley J, Andersson HC, Antshel KM, et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. <i>Genet Med</i>. 2014;16(2):188-200.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sapropterin-pediatric-drug-information/abstract-text/24385074/pubmed\" target=\"_blank\" id=\"24385074\">24385074</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 17134 Version 69.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F23322581\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F27147560\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F13706445\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F5568667\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F24036978\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F13706446\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F5568649\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F13706416\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F5568565\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F5568582\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F5568576\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F5568577\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300027\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F5568645\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F5568572\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5568573\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F13706447\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F28209766\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F5568650\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F5568652\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16321796\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961933\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/17134|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=sapropterin-drug-information\" class=\"drug drug_general\">Sapropterin: Drug information</a></li><li><a href=\"topic.htm?path=sapropterin-patient-drug-information\" class=\"drug drug_patient\">Sapropterin: Patient drug information</a></li></ul></div></div>","javascript":null}